Green Bioactives appoints experienced biotech leaders Chris Meaney and Andy Hall-Ponselé to expand senior management team
January 17, 2023Business Services
Edinburgh, Scotland, 17 January 2023 – Green Bioactives Limited (‘GBL’), a world-leader in the discovery, development and sustainable production of …
AstraZeneca UK, Qure.ai and Greater Manchester Cancer Alliance Join Forces to Battle Lung Cancer Waiting Times Using Artificial Intelligence (AI) Technology
January 17, 2023Business Services
London, UK, 13 January 2023 – An initiative to improve earlier diagnosis of lung cancer has been launched by AstraZeneca UK, …
The Scottish Medicines Consortium recommends Merck’s TEPMETKO® (tepotinib) as the first oral MET inhibitor treatment option for advanced NSCLC adult patients with METex14 skipping alterations
January 16, 2023Business Services
16 January 2023, Feltham (Merck) – Today Merck, a leading science and technology company, announced that following a resubmission to …
Boehringer Ingelheim and 3T Biosciences form $268m partnership to develop next-generation cancer immunotherapies
January 16, 2023Medical Communications
Germany-based Boehringer Ingelheim and US company 3T Biosciences have entered into a strategic collaboration and licensing agreement to research and …
Eli Lilly and AbbVie leave UK VPAS; blow to UK pharma industry
January 16, 2023Medical Communications
Eli Lilly and AbbVie have announced their departure from the voluntary scheme for branded medicines pricing and access (VPAS), causing …
Luye Pharma’s Rykindo® approved by FDA for treatment of schizophrenia and bipolar 1 disorder
January 16, 2023Research and Development
International pharmaceutical company, Luye Pharma, has announced that Rykindo® has received FDA approval for the treatment of schizophrenia in adult …
AstraZeneca’s Tezspire gains CHMP approval for the treatment of severe asthma
January 16, 2023Research and Development
AstraZeneca has announced that Tezspire (also known as tezepelumab) has received approval from the EMA’s Committee for Medicinal Products for …
Poolbeg announces strategic expansion of POLB 001 into oncology
January 16, 2023Business Services
16 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
finnCap Cavendish advises on the sale of MBI Healthcare Technologies to DNV
January 13, 2023Business Services
London, 9th January – finnCap Cavendish, part of finnCap Group plc, is pleased to announce it has advised the three …
Pfizer’s COVID-19 vaccine under FDA’s examination following new research into adverse side effects
January 13, 2023Medical Communications
The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known …
Diabeloop and EOFlow team up to develop an automated insulin device
January 13, 2023Medical Communications
Diabeloop, a medical device company focused on automated diabetes treatment solutions, and South Korea-based EOFlow have joined forces to offer …
First patient enrolled in Inari DEFIANCE trial for deep vein thrombosis
January 13, 2023Research and Development
Inari Medical has announced that the first patient has been enrolled in the DEFIANCE trial. This trial will evaluate the …
MediciNova completes enrolment for phase 2 clinical trial of ibudilast to treat recurrent and newly diagnosed glioblastoma
January 13, 2023Research and Development
Biopharmaceutical company MediciNova has announced that its phase 2 clinical trial to assess MN-166 (ibudilast) for the treatment of recurring …
Ajinomoto and Exelixis sign agreement to develop novel ADCs for cancer treatment
January 12, 2023Research and Development
Ajinomoto Co., a Japanese biotech company providing biopharmaceuticals, has signed a license agreement with Exelixis Inc., an oncology-focused biotech company, …
BD showcase new-generation robotic track system for microbiology labs
January 12, 2023Medical Communications
US-based Becton, Dickinson and Company (BD) has revealed new-generation robotic track system for its BD Kiestra microbiology laboratory solution which …
Oramed shares disappointing top-line results from phase 3 trial for type 2 diabetes treatment
January 12, 2023Research and Development
Clinical stage pharmaceutical company, Oramed Pharmaceuticals, has announced top-line results from its phase 3 randomised, double-blind, placebo-controlled, multicentre trial, which …
Alvotech’s golimumab biosimilar phase 1 trial begins
January 12, 2023Research and Development
Alvotech has announced that it has begun a phase 1 study evaluating the safety, tolerability and pharmacokinetics of its golimumab …
Avillion announces US approval of AstraZeneca’s Airsupra (PT027) as new rescue treatment for asthma
January 11, 2023Business Services
London, UK, 11 January 2023 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical …
Ovarian Cancer Commitment launches digital patient support resource for anyone affected by ovarian cancer
January 11, 2023Business Services
28 October 2022, 10:00 BST
New technology to “unlock” NHS records to revolutionise how we take medicine
January 11, 2023Business Services
London, UK – New technology which can “unlock” medication records has been awarded £1m in fresh funding by Innovate UK.
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
